O-1918
O-1918
|
Systematic (IUPAC) name |
---|
1,3-dimethoxy-5-methyl-2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene |
Clinical data |
---|
Identifiers |
---|
|
536697-79-7 |
---|
PubChem |
CID 40469923 |
---|
Chemical data |
---|
Formula |
C19H26O2 |
---|
|
286.19 |
---|
SMILES
- CC1=C[C@@H](C2=C(OC)C=C(C)C=C2OC)[C@H](C(C)=C)CC1
|
O-1918 is a synthetic compound related to cannabidiol, which is an antagonist at two former orphan receptors GPR18 and GPR55, that appear to be related to the cannabinoid receptors. O-1918 is used in the study of these receptors, which have been found to be targets for a number of endogenous and synthetic cannabinoid compounds, and are thought to be responsible for most of the non-CB1, non-CB2 mediated effects that have become evident in the course of cannabinoid research.[1][2][3][4][5]
See also
References
- ↑ Offertáler, L.; Mo, F. M.; Bátkai, S.; Liu, J.; Begg, M.; Razdan, R. K.; Martin, B. R.; Bukoski, R. D.; Kunos, G. (2003). "Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor". Molecular Pharmacology 63 (3): 699–705. doi:10.1124/mol.63.3.699. PMID 12606780.
- ↑ Zakrzeska, A.; Schlicker, E.; Baranowska, M.; Kozłowska, H.; Kwolek, G.; Malinowska, B. (2010). "A cannabinoid receptor, sensitive to O-1918, is involved in the delayed hypotension induced by anandamide in anaesthetized rats". British Journal of Pharmacology 160 (3): 574–584. doi:10.1111/j.1476-5381.2009.00579.x. PMC 2931558. PMID 20105178.
- ↑ Schuelert, N.; McDougall, J. J. (2011). "The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55". Neuroscience Letters 500 (1): 72–76. doi:10.1016/j.neulet.2011.06.004. PMID 21683763.
- ↑ Szczesniak, A. M.; Maor, Y.; Robertson, H.; Hung, O.; Kelly, M. E. M. (2011). "Nonpsychotropic Cannabinoids, Abnormal Cannabidiol and Canabigerol-Dimethyl Heptyl, Act at Novel Cannabinoid Receptors to Reduce Intraocular Pressure". Journal of Ocular Pharmacology and Therapeutics 27 (5): 427–435. doi:10.1089/jop.2011.0041. PMID 21770780.
- ↑ Caldwell, M. D.; Hu, S. S. J.; Viswanathan, S.; Bradshaw, H.; Kelly, M. E.; Straiker, A. (2013). "A GPR18-based signaling system regulates IOP in murine eye". British Journal of Pharmacology 169 (4): 834–43. doi:10.1111/bph.12136. PMC 3687663. PMID 23461720.
|
---|
| Phytocannabinoids | |
---|
| Cannabinoid metabolites | |
---|
| Endogenous cannabinoids | |
---|
| Synthetic cannabinoid receptor agonists | Classical cannabinoids (Dibenzopyrans) | |
---|
| Nonclassical cannabinoids | |
---|
| Benzoylindoles | |
---|
| Naphthoylindoles | |
---|
| Naphthoylindazoles | |
---|
| Pyrrolobenzoxazines | |
---|
| Naphthylmethylindoles | |
---|
| Phenylacetylindoles | |
---|
| Indole-3-carboxamides | |
---|
| Indole-3-carboxylates | |
---|
| Indazole-3-carboxamides | |
---|
| Naphthoylpyrroles | |
---|
| Eicosanoids | |
---|
| Others | |
---|
|
---|
| Allosteric modulators of cannabinoid receptors | |
---|
| Endocannabinoid activity enhancers | |
---|
| Cannabinoid receptor antagonists and inverse agonists | |
---|
|
|
---|
| Receptor (ligands) | |
- Note: The above list contains only some known CB1R agonists, as too many exist to list here completely. Refer here instead for more.
|
---|
| |
- Agonists: 2-AG
- 2-AGE (noladin ether)
- 4-O-Methylhonokiol
- A-796,260
- A-834,735
- A-836,339
- AM-1221
- AM-1235
- AM-1241
- AM-2232
- Anandamide
- AZ-11713908
- Cannabinol
- Caryophyllene
- CBS-0550
- CP-55,940
- GW-405,833 (L-768,242)
- GW-842,166X
- HU-308
- JTE 7-31
- JWH-007
- JWH-015
- JWH-018
- JWH-73
- JWH-133
- L-759,633
- L-759,656
- Magnolol
- MDA-19
- Nabitan
- PF-03550096
- S-444,823
- SER-601
- Serinolamide A
- UR-144
- Tedalinab
- THC (dronabinol)
- THCV
- Tetrahydromagnolol
- Virodhamine
|
---|
| | |
---|
| | |
---|
| | |
---|
|
---|
| Transporter (inhibitors) | |
---|
| Enzyme (inhibitors) | | |
---|
| |
- IDFP
- JZL-184
- JZL-195
- URB-602
|
---|
| | |
---|
|
---|
|